Sekine Shuichi, Mitsuki Kaori, Ito Kousei, Kugioka Satoe, Horie Toshiharu
Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8675, Japan.
Biochim Biophys Acta. 2012 Jun;1822(6):980-7. doi: 10.1016/j.bbadis.2012.01.015. Epub 2012 Feb 8.
Multidrug resistance-associated protein 2 (MRP2) is a member of a family of efflux transporters that are involved in biliary excretion of organic anions from hepatocytes. Disrupted canalicular localization and decreased protein expression of MRP2 have been observed in patients with chronic cholestatic disorder and hepatic failure without a change in its mRNA expression. We have previously demonstrated that post-transcriptional regulation of the rapid retrieval of rat MRP2 from the canalicular membrane to the intracelluar compartment occurs under conditions of acute (~30min) oxidative stress. However, it is unclear whether MRP2 expression is decreased during its sustained internalization during chronic oxidative stress. The present study employed buthionine sulfoximine (BSO) to induce chronic oxidative stress in the livers of Sprague-Dawley rats and then examined the protein expression and localization of MRP2. Canalicular MRP2 localization was altered by BSO treatment for 2h without changing the hepatic protein expression of MRP2. While the 8h after exposure to BSO, hepatic MRP2 protein expression was decreased, and the canalicular localization of MRP2 was disrupted without changing the mRNA expression of MRP2. The BSO-induced reduction in MRP2 protein expression was suppressed by pretreatment with N-benzyloxycarbonyl (Cbz)-Leu-Leu-leucinal ( MG-132), a proteasomal inhibitor. Furthermore, the modification of MRP2 by small ubiquitin-relatedmodifier 1 (SUMO-1) was impaired in BSO-treated rat liver,while that by ubiquitin (Ub) and MRP2 was enhanced. Taken together, the results of this study suggest the sustained periods of low GSH content coupled with altered modification of MRP2 by Ub/SUMO-1 were accompanied by proteasomal degradation of MRP2.
多药耐药相关蛋白2(MRP2)是外排转运蛋白家族的成员之一,参与肝细胞中有机阴离子的胆汁排泄。在慢性胆汁淤积性疾病和肝衰竭患者中,已观察到MRP2的胆小管定位破坏和蛋白表达降低,而其mRNA表达无变化。我们之前已经证明,在急性(约30分钟)氧化应激条件下,大鼠MRP2会从胆小管膜快速回收至细胞内区室,这一过程存在转录后调控。然而,尚不清楚在慢性氧化应激期间MRP2持续内化过程中其表达是否会降低。本研究使用丁硫氨酸亚砜胺(BSO)诱导Sprague-Dawley大鼠肝脏发生慢性氧化应激,然后检测MRP2的蛋白表达和定位。BSO处理2小时后,MRP2的胆小管定位发生改变,但MRP2的肝脏蛋白表达未改变。而在暴露于BSO 8小时后,肝脏MRP2蛋白表达降低,MRP2的胆小管定位被破坏,而MRP2的mRNA表达未改变。蛋白酶体抑制剂N-苄氧羰基(Cbz)-亮氨酰-亮氨酰-亮氨酸醛(MG-132)预处理可抑制BSO诱导的MRP2蛋白表达降低。此外,在BSO处理的大鼠肝脏中,小泛素相关修饰物1(SUMO-1)对MRP2的修饰受损,而泛素(Ub)对MRP2的修饰增强。综上所述,本研究结果表明,低谷胱甘肽含量的持续期以及Ub/SUMO-1对MRP2修饰的改变伴随着MRP2的蛋白酶体降解。